Paspigioni is a full-service CRO that offers cost-effective, high-quality clinical trials from Phases I to IV. They also provide medical device studies, often with a rapid start-up. 

They operate across 19 emerging markets in Central and Eastern Europe, the Balkans, and Asia, ensuring a competitive edge for their partners. Using a CRO-in-a-box approach, Paspigioni launches and manages trials in different countries and supports biotech and pharma companies with efficient solutions. They guide their partners through new clinical landscapes, offering operational excellence and reliable results. They enable access to untapped patient populations, and provide local market expertise and a clear regulatory path.

Pencil Biosciences is developing a truly innovative gene editing technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. The technology is small, modular in design, and non-CRISPR in composition.

The Pharmaceutical Licensing Group, in the UK, has been established for 30 years and is the professional association for those active in pharmaceutical and biotechnology business development and licensing. 

There are around 200 members in the UK and over a 1000 in affiliated groups in Europe, Canada and Japan. All sectors of the industry are represented including multinationals, medium and small pharmaceutical companies, biotechnology, generic and consumer companies. 

The PLG is a not-for-profit organisation and is managed by a committee of licensing and business development executives from member companies. Details of the Committee members and how to contact them can be found by following the Committee link. 

The PLG organises meetings within local countries, a bi-annual European meeting and a bi-annual International meeting. Details of all meetings can be found on the Events page and by linking to other PLG sites on the European page. 

Physiomics develops mathematical models to predict the effect of therapeutic drugs. With an experienced team of dedicated scientists they work with their clients to answer their R&D questions and de-risk drug development.

Pictura Bio’s groundbreaking diagnostic platform was born out of a unique combination of medical and technical expertise in virology, biophysics and microscopy from the company’s co-founders, Dr Nicole Robb and Nicolas Shiaelis.

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.

Precision for Medicine, Oncology and Rare Disease is proud to offer the first comprehensive, fully integrated clinical development solution. We are devoted exclusively to oncology and rare disease, and our teams are passionate about improving the lives of these patients. By combining the progressive science of biomarkers and analytics with our excellence in complex clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.

Contact Precision for Medicine, Oncology and Rare Disease via their website